National Cancer Control Programme launched
India launches its first national cancer control programme, focused on awareness, palliative care and the slow build-up of cancer registries.
India has 1.46 million new cancer cases each year, and around 70 percent are diagnosed at Stage 3 or 4 when cure rates plummet. The problem is not cancer biology. It is the absence of screening.
Audio version coming soon
India's cancer burden is no longer a future concern, it is a present emergency. ICMR's National Cancer Registry Programme estimates 1.46 million new cases in 2024, with breast, oral, cervical, lung and gastrointestinal cancers leading. The deeper problem is timing. Tata Memorial Hospital and ICMR audits consistently show that around 70 percent of Indian cancer cases are diagnosed at Stage 3 or 4, when five-year survival drops sharply. Breast cancer, where a Stage 1 diagnosis has a 90 percent five-year survival rate, often presents at Stage 3 in Indian women with survival below 50 percent. Cervical cancer kills around 80,000 women a year despite being preventable through HPV vaccination and screening. Oral cancer takes around 80,000 lives despite being visible to any trained nurse. The core gap is not specialist oncology but everyday screening infrastructure, awareness and the social courage to seek care in time.
India's late diagnosis problem stems from a stacking of system, social and economic failures. First, there is no widespread organised cancer screening programme. Most district hospitals do not run mammography, Pap smears or HPV testing as routine, and visual inspection of the oral cavity is rarely integrated into general consultations. Second, awareness gaps mean women often dismiss early breast lumps or post-coital bleeding for months. Cervical cancer's typical 10-year pre-cancer window is lost without VIA, Pap or HPV testing. Oral cancer's premalignant lesions, leukoplakia and submucous fibrosis, are visible but ignored in tobacco-chewing communities. Third, financial fear keeps families away. The cost of a single mammography in a private centre is 1,500 to 3,000 rupees and a cytology smear 500 to 1,000, more than a day's wages for many. Fourth, social factors, especially shame around women's bodies, fear of cancer's stigma and the practice of going to traditional healers first, all add precious months before a patient reaches an oncologist.
Unread picks stay on top. Fresh stories may appear as they are ready โ no extra loading.
India now has 12 million obese children under 19, according to ICMR data. School canteens sell junk food while ultra-processed food advertising targets children.
India collects only 11 million units of blood annually against a need of 15 million. The O-negative shortage is acute, urban blood banks run on single-day reserves, and the rural gap is catastrophic.
India has fewer sports medicine doctors than many US college programs. Cricket and marathons grew fast; specialist care did not, so preventable injuries end careers early.
Biosimilars โ cheaper copies of complex biological drugs โ are worth 50 billion globally. Indian companies are racing to capture that market, threatening to cut the price of cancer and.
Micronutrient gaps hit rich and poor: anaemia stays high, vegetarians often lack B12, and urban adults lack vitamin D. Fortification and better diets can bend the curve if delivery improves.
127 essential medicines are out of stock in government hospitals across 12 states. The shortage hits insulin, antibiotics and cancer drugs. Central procurement failure exposes PM Jan Aushadhi gaps.
Key statistics on cancer in India:
Myth 1: Cancer is mostly bad luck, screening cannot change much. Fact: Cervical cancer is essentially preventable with HPV vaccination and three-yearly screening. Breast cancer detected at Stage 1 has 90 percent five-year survival. Oral cancer caught at a leukoplakia stage can be reversed by stopping tobacco and minor surgery. Screening is the strongest single tool we have, and India under-uses it severely.
Myth 2: A diagnosis of cancer is a death sentence in India. Fact: Outcomes for many cancers, including breast, paediatric leukaemia, thyroid and testicular, are now comparable to high-income countries when treatment is timely and complete. The biggest predictors of outcome are stage at diagnosis and continuity of treatment, not the diagnosis itself.
Myth 3: Discussing women's cancers in public is shameful. Fact: Cervical and breast cancers are the leading cancer killers of Indian women, and their early signs, post-coital bleeding, breast lumps and unexplained discharge, must be normalised in family conversations. Silence is one of the deadliest features of these cancers in India. ASHA-led talk groups, schoolgirl HPV vaccination drives and workplace cancer awareness sessions are slowly breaking the wall, but cultural change is slow.
Take Rekha Devi, a 38-year-old farm labourer in Uttar Pradesh who first noticed a breast lump in 2022 and went to a local Vaidya for poultices. By the time her daughter brought her to a Lucknow medical college in 2024, the cancer had spread to bones and liver. The family spent close to 6 lakh rupees on palliative care and lost her within nine months. Stories like Rekha's repeat across India. Tata Memorial's outreach in Vidarbha and Bihar shows that almost half of late-stage breast cancers presenting at its centres had a clear delay of more than six months between first symptom and any doctor visit. Oral cancer hits men in their forties who chew gutkha. Cervical cancer hits women whose Pap smears are simply never offered. The downstream impact runs deep, with families selling land for chemotherapy, children dropping out of school and elderly parents losing their only support. Free Ayushman Bharat oncology helps but cannot make up for years of missed prevention.
The bigger meaning of India's late-stage cancer pattern is that the country is investing in expensive end-stage treatment while missing the inexpensive early window where most cancers can be controlled. The long-term consequence is rising deaths, household impoverishment and an oncology system permanently in catch-up mode. The lesson from Sri Lanka's strong cervical screening, from Britain's national breast screening programme and from Thailand's HPV vaccine rollout is that organised, population-level screening saves more lives than any new drug. India has the architecture in Ayushman Bharat Health and Wellness Centres, ASHA networks and the National Cancer Grid. The future depends on whether HPV vaccination becomes a default school programme, whether VIA and Pap screening reach every CHC, whether oral cavity inspection is added to routine consultations and whether AYUSH-only first contact is supplemented with a clear referral path. Every Stage 1 diagnosis instead of Stage 3 is a life saved and a family's future preserved.
Chronology
Follow the arc from background to turning points. On mobile, swipe the cards and use the step rail below; on desktop, use the spine to jump.
India launches its first national cancer control programme, focused on awareness, palliative care and the slow build-up of cancer registries.
ICMR-NCDIR expands the cancer registry network across more states, producing the first comprehensive picture of stage at diagnosis and survival.
A landmark study in rural Maharashtra shows visual inspection with acetic acid for cervical cancer reduces mortality by around 31 percent, validating low-cost screening.
PM-JAY covers chemotherapy, surgery and radiation for eligible families, removing a major financial barrier for end-stage treatment but not screening.
The Tata Memorial-led National Cancer Grid expands its tele-mentoring and second-opinion network to over 280 centres, helping district hospitals match standardised care.
Cervavac, India's first indigenously developed HPV vaccine, becomes available, opening the door to a school-based vaccination programme at a fraction of the imported cost.
ICMR releases updated national cancer screening guidance with explicit protocols for breast, cervical and oral cancer at Health and Wellness Centres.
Step 1/7 events
Understand why it happened, how we got here, and what might come next.